Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Rahrig

Pain Medicine Mount Vernon, OH Medical Doctor

NPI 1003163403 CMS profile 590874

1330 Coshocton Ave, Ste 208, Mount Vernon, OH 43050

Open in the dashboard

General payments

$7,139

130 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Rahrig of Mount Vernon, OH is reported in the CMS Open Payments database as having received $7,139 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $584 12
2024 General $637 16
2023 General $1,336 21
2022 General $734 20
2021 General $821 15
2020 General $409 13
2019 General $2,618 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Rahrig
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Matthew Rahrig were reported at $584. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Matthew Rahrig Pain Medicine median Middle half National median
2019 $2,618 $498 $126–$1,682 $163
2020 $409 $284 $80–$910 $114
2021 $821 $399 $112–$1,219 $132
2022 $734 $455 $137–$1,484 $149
2023 $1,336 $484 $128–$1,495 $160
2024 $637 $498 $131–$1,540 $164
2025 $584 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,379 47 payments
  2. Vertos Medical, Inc. $1,735 20 payments
  3. Medtronic USA, Inc. $1,498 30 payments
  4. Nevro Corp. $344 9 payments
  5. SPR Therapeutics, Inc $243 6 payments
  6. Zynex Medical, Inc. $218 1 payment
  7. Foundation Fusion Solutions, LLC $208 6 payments
  8. BIOTRONIK NRO, Inc. $139 4 payments
  9. Boston Scientific Corporation $126 1 payment
  10. Stryker Corporation $123 3 payments
  11. Other $127 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,803 123 payments
  2. Travel and Lodging $1,195 5 payments
  3. Education $141 2 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $1,576 33 payments
  2. mild Device Kit Orthopedic $1,169 10 payments
  3. RESTORE Spinal Cord Neurostimulation $971 25 payments
  4. mild Device Kit Orthopedic $566 10 payments
  5. INTELLIS Spinal Cord Neurostimulation $527 5 payments
  6. INTELLIS Spinal Cord Neurostimulation $344 4 payments
  7. RESTORE Spinal Cord Neurostimulation $275 7 payments
  8. SPRINT PNS System $243 6 payments
  9. Omnia $233 7 payments
  10. Nexwave $218 1 payment
  11. Other $677 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

501

Median for Anesthesiology: 322

Drug cost

$5,841

Median for Anesthesiology: $8,738

Branded share of claims

17.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 222 $2,326
Pregabalin Generic 39 $1,013
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 43 $841
Diclofenac Sodium Generic 40 $318
Venlafaxine Hcl Er Venlafaxine Hcl Brand 29 $310
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 17 $273
Tizanidine Hcl Generic 37 $230
Methocarbamol Generic 14 $203
Meloxicam Generic 22 $185
Methylprednisolone Generic 17 $116

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$88,004

Medicare's payments for the services billed

Medicare patients

324

Average age 74

Services billed

1,077

186 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 34%
Depression 33%
Ischemic heart disease 31%
Diabetes 25%
Atrial fibrillation 19%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record